0.00Open0.30Pre Close0 Volume0 Open Interest17.50Strike Price0.00Turnover1684.18%IV0.96%PremiumOct 18, 2024Expiry Date0.13Intrinsic Value100Multiplier-2DDays to Expiry0.17Extrinsic Value100Contract SizeAmericanOptions Type-0.6791Delta0.8194Gamma57.89Leverage Ratio-97.0914Theta0.0000Rho-39.31Eff Leverage0.0001Vega
Boxman : Dr. Bart Van Putte, Cardiothoracic Surgeon at St. Antonius Hospital, used the Company’s Cardiac Surgery System to successfully treat two patients with atrial fibrillation at St. Antonius Hospital, Nieuwegein, The Netherlands. Dr. Van Putte was joined by colleagues and Pulse Biosciences’ Chief Medical Officer, Cardiac Surgery, Dr. Gan Dunnington and Chief Science Officer, Cardiac Surgery, Dr. Niv Ad during the concomitant procedure. The first-in-human feasibility study is a multicenter study of up to 30 patients that will include an endocardial catheter-based remapping to confirm chronic isolation at approximately three months post treatment